Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Radical S-adenosyl methionine domain-containing protein 1, mitochondrial (RSAD1) is a mitochondrial enzyme encoded by the RSAD1 gene in humans. It is classified as a member of the radical SAM superfamily of enzymes, predicted to facilitate reactions involving heme and porphyrin compounds, possibly acting as a heme chaperone or in an analogous pathway to oxygen-independent coproporphyrinogen-III oxidases seen in other species. RSAD1 binds iron–sulfur clusters and is localized to mitochondria. While expression profiles are catalogued across various tissues and in the context of cancer, there is currently no established evidence supporting its role as a therapeutic drug target, disease biomarker, or drug-interacting protein in clinical practice[2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Radical S-adenosyl methionine domain-containing protein 1, mitochondrial (RSAD1).